tadalafil – 1 a pharma 10mg film-coated tablets
1 a pharma gmbh - tadalafil - film-coated tablet - tadalafil 10 milligram(s) - urologicals
tadalafil – 1 a pharma 20 mg film-coated tablets
1 a pharma gmbh - tadalafil - film-coated tablet - tadalafil 20 milligram(s) - urologicals
celecoxib - 1 a pharma capsules hard 100mg
1 a pharma gmbh - celecoxib - hard capsule - celecoxib 100 milligram(s) - antiinflammatory and antirheumatic products
celecoxib - 1 a pharma capsules hard 200mg
1 a pharma gmbh - celecoxib - hard capsule - celecoxib 200 milligram(s) - antiinflammatory and antirheumatic products
tadalafil uropharm 5mg film-coated tablets
uropharm ag erfurtstrasse 64, 53125, bonn,, germany - tadalafil - film-coated tablet - tadalafil 5 mg - urologicals
tadalafil uropharm 10mg film-coated tablets
uropharm ag erfurtstrasse 64, 53125, bonn,, germany - tadalafil - film-coated tablet - tadalafil 10 mg - urologicals
tadalafil uropharm 20mg film-coated tablets
uropharm ag erfurtstrasse 64, 53125, bonn,, germany - tadalafil - film-coated tablet - tadalafil 20 mg - urologicals
cilostazol sandoz 100mg tablets
hexal pharma gmbh stella-klein-low-weg 17, 1020 wein, austria - cilostazol - tablet - cilostazol 100 mg - antithrombotic agents
clopidogrel hexal
acino pharma gmbh - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;patients suffering from acute coronary syndrome:- non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.
clopidogrel sandoz
acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:* patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.